Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer

Background Ovarian cancer (OvCa) is the most lethal of the gynecologic malignancies. Immune checkpoint inhibitors, which have revolutionized the treatment of multiple malignancies, have had limited efficacy in OvCa patients. This lack of effectiveness is partly due to the abnormal ovarian tumor micr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2024-11, Vol.131 (10), p.1683-1693
Hauptverfasser:	Sun, Yao, Yin, Zhenzhen, Li, Shuang, Wu, Limeng, Zhang, Yanling, Zhao, Yanxia, Gomes dos Santos, Igor L., Subudhi, Sonu, Lei, Pinji, Muzikansky, Alona, Yuan, Zhiyong, Rueda, Bo R., Jain, Rakesh K., Xu, Lei
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/152 631/67/1517/1709 Animals Antihypertensives Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell culture Cell Line, Tumor Cytotoxicity Drug delivery Drug Resistance Drug Resistance, Neoplasm - drug effects Effector cells Epidemiology Extracellular matrix Female Humans Immune checkpoint inhibitors Immunosuppressive agents Immunotherapy Immunotherapy - methods Insulin-like growth factor I Insulin-Like Growth Factor I - metabolism Losartan - pharmacology Losartan - therapeutic use Lymphocytes T Malignancy Metastases Mice Molecular Medicine Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Perfusion Tumor microenvironment Tumor Microenvironment - drug effects Tumor Microenvironment - immunology Tumors Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!